Aromatase inhibition plus/minus Src inhibitor saracatinib (AZD0530) in advanced breast cancer therapy (ARISTACAT): a randomised phase II study

PURPOSE: The development of oestrogen resistance is a major challenge in managing hormone-sensitive metastatic breast cancer. Saracatinib (AZD0530), an oral Src kinase inhibitor, prevents oestrogen resistance in animal models and reduces osteoclast activity. We aimed to evaluate the efficacy of sara...

Descripción completa

Detalles Bibliográficos
Autores principales: Oswald, Ailsa J., Symeonides, Stefan N., Wheatley, Duncan, Chan, Stephen, Brunt, Adrian Murray, McAdam, Karen, Schmid, Peter, Waters, Simon, Poole, Christopher, Twelves, Chris, Perren, Timothy, Bartlett, John, Piper, Tammy, Chisholm, Eve Macdonald, Welsh, Michelle, Hill, Robert, Hopcroft, Lisa E. M., Barrett-Lee, Peter, Cameron, David A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10147753/
https://www.ncbi.nlm.nih.gov/pubmed/36859649
http://dx.doi.org/10.1007/s10549-023-06873-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10147753/
https://www.ncbi.nlm.nih.gov/pubmed/36859649
http://dx.doi.org/10.1007/s10549-023-06873-8

Ejemplares similares